MetaCap

Adaptive Biotechnologies (ADPT) vs Vericel (VCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adaptive Biotechnologies (ADPT) has outperformed Vericel (VCEL) over the past year, gaining 50.1% versus a gain of 45.3%. Over five years, VCEL leads with a +50.1% price change compared with -0.7% for ADPT. Adaptive Biotechnologies is the larger company by market cap ($4.52 billion vs $2.94 billion), about 1.5 times the size.

Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -21.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADPT+50.08%VCEL+45.33%
+67%+15%-38%
Nov 21, 20251 yearNov 20, 2026
ADPT+2.12%VCEL+29.75%
+40%-29%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADPT versus VCEL key metrics
MetricADPTVCEL
Share price$27.93$57.52
Market cap$4.52B$2.94B
1-day change-0.43%-1.27%
YTD return+71.98%+59.73%
1-year return+50.08%+45.33%
5-year return-0.68%+50.14%
P/E ratio (TTM)—89.88
Forward P/E—61.06
EPS (TTM)$-0.45$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$276.98M$276.26M
Revenue growth (YoY)+54.77%+16.45%
Net income (latest FY)$-59.50M$16.52M
Gross margin74.24%74.42%
Operating margin-20.62%4.00%
Net margin-21.48%5.98%
52-week high$32.21$59.75
52-week low$12.00$28.95
Distance from 52-week high-13.29%-3.73%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+21.23%+13.75%
Average volume2.20M664.34K
Shares outstanding161.88M51.03M
Employees624398
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -21.5 cents for Adaptive Biotechnologies.
  • Adaptive Biotechnologies grew revenue faster in its latest fiscal year (+54.77% vs +16.45%).

About Adaptive Biotechnologies

ADPT stock →

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees

About Vericel

VCEL stock →

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees

ADPT vs VCEL FAQ

Which is bigger, Adaptive Biotechnologies or Vericel?

Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.52B compared with $2.94B for Vericel (VCEL).

Which stock has performed better over the past year, ADPT or VCEL?

ADPT returned +50.08% over the past 12 months, compared with +45.33% for VCEL (price return, excluding dividends). Past performance does not predict future results.

Are Adaptive Biotechnologies and Vericel in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons